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doi:10.1016/j.kjms.2011.11.011Abstract The emergence of antifungal resistance in Candida species has raised concern in
recent years, especially resistance toward triazole. Several newer triazole antifungal agents
have been introduced which have a broader spectrum for fungal infections, such as voricona-
zole. However, cross-resistance among triazoles is a major concern with regard to their clinical
application. Antifungal susceptibility was performed using E-test for 166 clinical isolates (29
blood and 137 nonblood isolates) in 2003 and 2004. We applied pulsed-field gel electrophoresis
for genotyping. Ninety isolates of C. albicans, 47 isolates of C. tropicalis, 27 isolates of C. glab-
rata, and two isolates of C. krusei were included. All isolates were susceptible to amphotericin
B. Eleven (40.7%) of the 27 C. glabrata had intermediate resistance to caspofungin. Forty-
seven (28.3%) of the 166 isolates were not susceptible to fluconazole, including two C. albi-
cans, 16 C. tropicalis, 27 C. glabrata, and two C. krusei isolates. All except seven of the
C. glabrata isolates were susceptible to voriconazole. All the triazole drugs had a positive
correlation among their minimum inhibitory concentrations (MICs). Fluconazole MIC was a good
predictor for susceptibility to voriconazole, as determined using a receiver operating, Tzyou 1st Road 807, Kaohsiung City, Taiwan.
edu.tw (P.-L. Lu).
vier Taiwan LLC. All rights reserved.
Fluconazole use and triazole cross-resistance 307characteristic curve. Furthermore, a high diversity of pulsotypes for the 27 clinical isolates of
C. glabrata was observed. Previous fluconazole exposure within 3 months was associated with
reduced triazole susceptibility for C. glabrata. We demonstrated a significant positive correla-
tion of MIC values among the four tested triazole drugs. No amphotericin B and caspofungin
resistant isolates were found in this study. The cross-resistance to triazole among C. glabrata
isolates was associated with previous fluconazole exposure as opposed to clonal spreading.
Selection pressure due to fluconazole use may play a major role in triazole cross-resistance.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.Introduction
Candida infections have become more prevalent in recent
decades because of the increasing number of immuno-
compromised hosts and critically ill patients [1,2]. In
Taiwan, Candida species were the first and the second most
common pathogens of nosocomial infections in medical
centers and regional hospitals, respectively, in 2008 [3].
Fluconazole has been the most widely used antifungal
agent for invasive candidiasis since the 1990s, and concern
over the emergence of fluconazole resistance has risen,
especially with the increasing use of fluconazole for the
treatment and prophylaxis of candidal infections [2]. A
nationwide survey across Taiwan showed increasing fluco-
nazole resistance rates, from 1.9% in 2002 to 17.1% in 2006,
especially among nonblood or nonalbicans isolates [4].
Furthermore, co-resistance to both amphotericin B and
fluconazole has been observed, indicating a serious
problem for the treatment of these infections [4]. The
increasing seriousness of Candida infections within hospi-
tals with regard to the increasing incidence and resistance
rates in Taiwan is reflected worldwide [2]. However, the
threat of fluconazole resistance rates in C. glabrata in
southern Taiwan is particularly serious, with two nation-
wide surveys reporting 40e81% of isolates with non-
susceptibility [5,6].
Although antifungal susceptibility testing is not routinely
performed, local reference data for antifungal suscepti-
bility and the epidemiology of species distribution, the
existence of occult outbreaks of resistant strains, and the
analysis of risk factors relevant to resistance are impor-
tant. Antimicrobial resistance originates from either anti-
microbial selection pressure or a resistant gene having
spread clonally. Here we report the analysis of 166 clinical
isolates from a Taiwan medical center and compare the
data of candidemia isolates from 1998 [7] to elucidate
the change in antifungal resistance and its possible
mechanisms.
Material and methods
Study duration and population
All Candida species for this study were consecutively iso-
lated from clinical specimens of Kaohsiung Medical
University Hospital between September 1, 2003, and May
31, 2004, and sputum specimens that were not confirmed to
be Candida pneumonia were excluded. Only the first
Candida isolate of multiple isolates of the same species and
from the same patient was included for further study. Chartreview was performed to collect patient demographic
information, including medical history (malignancy, total
parenteral nutrition, neutropenia, intensive care unit
admission, diabetes mellitus, hypertension, and any
underlying diseases), invasive procedures (including use of
ventilator, urinary catheters, among others), use of
immunosuppression drugs and antifungal agents (drugs for
more than 1 day, within 3 months), and laboratory data
using a standardized case record form.
Clinical Candida isolates were identified to the species
level by colonial characteristics, microscopic features,
carbohydrate assimilation-fermentation studies, and germ
tube tests, and then confirmed using the ID 32 C system
(bioMerieux, Hazelwood, MO, USA). Antifungal susceptibility
testing was performed and minimum inhibitory concentra-
tions (MICs) were determined by the E-test method (AB Bio-
disk, Solna, Sweden) for amphotericin B, fluconazole,
itraconazole, ketoconazole, voriconazole, and caspofungin.
RPMI-1640 agar buffered with 4-morpholinepropanesulfonic
acid (MOPS, pH 7.0) was prepared for the E-tests. A total of
0.5McFarland standard inoculawereapplied to theRPMI agar
with a cotton swab. The MIC endpoints were read after 48
hours of incubation at 35 C [8e10]. C. albicans ATCC 90028,
C. krusei ATCC 6258, and C. parapsilosis ATCC 22019 were
used as control strains. Results for susceptibility were
considered eligible only when the MICs of the control strains
were all within the standard range [11].We used the recently
revised the Clinical and Laboratory Standards Institute (CLSI)
clinical breakpoints to define susceptibility categories of
Candida isolates to caspofungin and fluconazole [12,13].
Caspofungin MIC values of S1 mg/mL were considered
resistant for C. albicans, C. tropicalis, and C. krusei, andMIC
results of S8 mg/mL were categorized as resistant for
C. parapsilosis; caspofungin MIC values ofS0.5 mg/mL were
considered resistant for C. glabrata. Fluconazole MIC results
of S8 mg/mL were defined as resistant for C. albicans,
C. parapsilosis, and C. tropicalis, and MICsS64 mg/mL were
considered resistant for C. glabrata. All isolates of C. krusei
were defined as resistant to fluconazole. Interpretative
criteria of susceptibility for Candida species to itraconazole
andvoriconazolewere in accordancewith theCLSI guidelines
in 2008 [14]. Isolates with an itraconazole MIC of0.125 mg/
ml were classified as S, those with an itraconazole MIC of
>0.5 mg/ml were classified as resistance (R), and those in
between were classified as susceptible-dose dependent (S-
DD). Susceptibility to voriconazole was defined as a vor-
iconazole MIC  1 mg/mL. Amphotericin B-resistant Candida
isolates were defined as those with an amphotericin B
MIC > 1 mg/mL, as previously proposed [15]. Ketoconazole-
resistant Candida isolates were defined as those with
a ketoconazole MIC > 0.125 mg/mL [16].
Table 1 MICs and antifungal susceptibility of Candida species.
Species
(isolates)
Amphotericin B Fluconazole Itraconazole Ketoconazole Voriconazole Caspofungin
Range S/R Range S/SDD/Ra S/SDD/Rb Range S/SDD/R Range S/R Range S/SDD/R Range S/Ra S/I/Rb
S% S%a S%b S% S% S% S%a S%b
C. albicans
Blood (21) 0.004e0.25 21/0 0.38 e >256 20/0/1 20/0/1 0.016 e >32 20/0/1 0.006 e >32 20/1 0.012e0.047 21/0/0 0.047e0.125 21/0 21/0/0
100 95.2 95.2 95.2 95.2 100 100 100
Urine (52) 0.008e0.19 52/0 0.125 e >256 51/0/1 51/0/1 0.012 e >32 47/4/1 0.006 e >32 51/1 0.008e0.032 52/0/0 0.047e0.125 52/0 52/0/0
100 98.1 98.1 90.4 98.1 100 100 100
Other (17) 0.012e0.25 17/0 0.38e1.5 17/0/0 17/0/0 0.032e0.19 16/1/0 0.004e0.032 17/0 0.008e0.047 16/0/0 0.047e0.125 17/0 17/0/0
100 100 100 94.1 100 100 100 100
Subtotal (90) 0.004e0.25 90/0 0.125 e >256 88/0/2 88/0/2 0.012 e >32 83/5/2 0.004 e >32 88/2 0.008e0.047 89/0/0 0.047e0.125 90/0 90/0/0
100 97.8 97.8 92.2 97.8 100 100 100
C. tropicalis
Blood (7) 0.016e0.5 7/0 1e8 7/0/0 6/0/1 0.064e1 4/1/2 0.023e0.125 7/0 0.047e0.38 7/0/0 0.094e0.125 7/0 7/0/0
100 100 85.7 57.1 100 100 100 100
Urine (35) 0.012e0.5 35/0 0.25e12 33/2/0 23/7/5 0.012e2 14/8/13 0.006e0.125 35/0 0.016e0.5 35/0/0 0.064e0.125 35/0 35/0/0
100 94.3 65.7 40 100 100 100 100
Other (5) 0.016e0.5 5/0 1e8 5/0/0 2/2/1 0.125e3 1/1/3 0.023e0.125 5/0 0.064e0.38 5/0/0 0.064e0.125 5/0 5/0/0
100 100 40.0 20 100 100 100 100
Subtotal (47) 0.012e0.5 47/0 0.25e12 45/2/0 31/9/7 0.012e3 19/10/18 0.006e0.125 47/0 0.016e0.5 47/0/0 0.064e0.125 47/0 47/0/0
100 95.7 66.0 40.4 100 100 100 100
C. glabrata
Blood (1) 0.064 1/0 3.000 1/0/0 0/1/0 0.125 1/0/0 0.064 1/0 0.047 1/0/0 0.125 1/0 0/1/0
100 100 0 100 100 100 100 0
Urine (20) 0.023e0.38 20/0 2e256 8/4/8 0/12/8 0.125e32 2/3/15 0.023e6 7/13 0.032e6 13/0/7 0.012e0.19 20/0 15/5/0
100 40 0 10 35.0 65 100 75.0
Other (6) 0.023e0.5 6/0 3e12 4/2/0 0/6/0 0.125e3 1/1/4 0.125e0.25 2/4 0.094e0.38 6/0/0 0.064e0.47 6/0 1/5/0
100 66.7 0 16.7 33.3 100 100 16.7
Subtotal (27) 0.023e0.5 27/0 2e256 13/6/8 0/19/8 0.125e32 4/4/19 0.023e6 10/17 0.032e6 20/0/7 0.012e0.47 27/0 16/11/0
100 48.1 0 14.8 37.1 74.1 100 59.3
C. krusei
Blood (0) d d d d d d d d d d d d d d
d d d d d d d d d d d d d
Urine (2) 0.047e0.75 2/0 64 e >256 0/0/2 0/0/2 1.5e4 0/0/2 0.5e0.75 0/2 0.25e0.38 2/0/0 0.19e0.25 2/0 2/0/0
100 0 0 0 0 100 100 100
Other (0) d d d d d d d d d d d
d d d d d d d d d d d d
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Fluconazole use and triazole cross-resistance 309Genotyping using pulsed field gel electrophoresis
Pulsed field gel electrophoresis (PFGE) for C. glabrata
utilized the restriction enzymes SfiI and BssHII, as previ-
ously described [17]. To identify PFGE polymorphisms, each
sample was analyzed using Molecular Analyst Finger-
printing, Fingerprinting Plus, and Fingerprinting DST soft-
ware (Bio-Rad Laboratories, Richmond, CA, USA). The
grouping method was performed to produce a dendrogram
from the matrix via the unweighted pair group method
using the arithmetic average clustering technique after
calculating similarities using Pearson correlation coefficient
between every pair of organisms.
Statistical analysis
All data were analyzed using SPSS version 17.0 (SPSS
Inc., Chicago, IL, USA). Categorical variables were
compared using univariate analysis with the Chi-square
test. Continuous variables were analyzed with the
student t test or one-way analysis of variance (ANOVA).
A p value of <0.05 was considered statistically significant
(two-tailed). Multivariate analyses were conducted using
a logistic regression model for the variables that were
significant in the univariate analysis. Pairwise correla-
tions of the logarithm of six antifungal MICs to the base
2 (Log2) were performed using JMP version 7.0 (SAS
Institute, NC, USA). A receiver operating characteristic
(ROC) curve was used to determine the optimal cutoff
point of MICs for fluconazole, itraconazole, and ketoco-
nazole to predict voriconazole nonsusceptibility, which
was performed using MedCalc version 10.2.0.0 (MedCalc,
Mariakerke, Belgium).
Results
From September 1, 2003, through May 31, 2004, a total of
166 clinical isolates (29 blood and 137 nonblood isolates)
were collected. There were 90 isolates (90/166, 54.2%) of
C. albicans, 47 of C. tropicalis, 27 of C. glabrata, and two
of C. krusei. The susceptibility to antifungal agents of the
various species and specimen origins is shown in Table 1. All
isolates were susceptible to amphotericin B. Eleven (40.7%)
of the 27 C. glabrata showed intermediate resistance to
caspofungin. Forty-seven (28.3%) of the 166 isolates were
not susceptible to fluconazole, including two C. albicans,
16 C. tropicalis, 27 C. glabrata, and two C. krusei isolates.
All isolates were susceptible to voriconazole except for
seven isolates of C. glabrata obtained from urine speci-
mens. The co-resistance relationships of the six antifungal
agents were examined by paired correlation of Log2 values
of MICs (Fig. 1). All the triazole drugs (fluconazole, keto-
conazole, itraconazole, and voriconazole) had MIC values
that demonstrated a high correlation to each other in that
all combinations had correlation coefficients >0.74. The
susceptibility of the older triazoles (fluconazole, itracona-
zole, and ketoconazole) also had a significant linear
correlation to voriconazole against C. glabrata (p values of
Spearman correlation: < 0.001 for fluconazole, 0.02 for
itraconazole, and 0.01 for ketoconazole). However, only
the susceptibility of fluconazole could significantly predict
Figure 1. Scatterplot matrix and pairwise correlation of log2 values for the minimum inhibitory concentrations of the six tested
antifungal agents.
310 T.-C. Chen et al.the susceptibility of C. glabrata for voriconazole
(p < 0.001) (Table 2). An ROC curve was used to determine
the cut-off MIC values of fluconazole, itraconazole, or
ketoconazole for nonsusceptibility of C. glabrata and all
Candida species to voriconazole. Significant high areas
under the curve and likelihood ratios are shown in Fig. 2A,
when MICs of fluconazole >16 mg/ml, itraconazole >3 mg/
ml, and ketoconazole >1.5 mg/ml to predict C. glabrata
nonsusceptibility to voriconazole. Significant high areas
under the curve and likelihood ratios are also shown inTable 2 The correlation of susceptibility to different triazoles
Isolates Fluconazole
All Candida species S SDD
Voriconazole susceptible 146a 8a
119b 28b
Voriconazole nonsusceptible 0 0
Chi-square test p value <0.001a,b
Spearman correlation p value <0.001a,b
Candida glabrata S SDD
Voriconazole susceptible isolates 13a 6a
0 b 19b
Voriconazole nonsusceptible isolates 0 0
Chi-square test p value <0.001a,b
Spearman correlation p value <0.001a,b
CLSI Z Clinical and Laboratory Standards Institute; MIC Z minimu
SDD Z susceptible-dose dependent.
a Antifungal susceptibility test interpretive category by CLSI M27-A
b Antifungal susceptibility test interpretive category by updated CLFig. 2B, when MICs of fluconazole >64 mg/ml, itraconazole
>4 mg/ml, and ketoconazole >1.5 mg/ml to predict vor-
iconazole nonsuscetibility for all Candida species. There
was no linear relationship among amphotericin B, caspo-
fungin, and the four tested azole drugs. There was also no
significant relationship between amphotericin B and cas-
pofungin (correlation coefficient: 0.0116, p Z 0.883).
With regard to the typing result of the 27 C. glabrata
isolates, four (14.8%) isolates that were susceptible to both
voriconazole and fluconazole were of the same pulsotype.and the prediction of voriconazole susceptibility.
Itraconazole Ketoconazole
R S SDD R S R
5a 145 9 5 106 53
12b
7 0 0 7 0 7
<0.001 <0.001
<0.001 <0.001
R S SDD R S R
1a 4 6 10 10 10
1b
7 0 0 7 0 7
0.062 0.057
0.021 0.017
m inhibitory concentration; R Z resistance; S Z susceptible;
3 (2008).
SI criteria (2011).
Figure 2. (A) Using the ROC curve method to determine cut-off MIC values of surrogate markersdfluconazole, itraconazole, or
ketoconazoledfor voriconazole nonsusceptibility of C. glabrata; (B) using the ROC curve method to determine cut-off MIC values of
surrogate markersdfluconazole, itraconazole, or ketoconazoledfor voriconazole nonsusceptibility of the Candida species.
MIC Z minimum inhibitory concentration; ROC Z receiver operating characteristic.
Fluconazole use and triazole cross-resistance 311The majority of the isolates, however, were not of identical
pulsotypes (Fig. 3). This indicated that there was no clonal
transmission of voriconazole-resistant C. glabrata.
Excluding 12 cases whose clinical data were not
adequately collected, the clinical characteristics of 154
cases were further correlated with species and suscepti-
bility differences. There was no correlation between
Candida species and specimen types. No factor of demo-
graphics, underlying disease, or invasive procedure was
significantly related with a specific Candida species (we
excluded C. krusei from the analysis due to its small case
number). Only fluconazole exposure in the last 3 months
was significantly associated with geometric means of
MIC for fluconazole, itraconazole, and ketoconazole
(p Z 0.012, 0.006, and 0.028, respectively) against
C. glabrata, and fluconazole exposure in the last 3 months
was also marginally associated with the MIC for vor-
iconazole (p Z 0.051). There was also a significant associ-
ation between fluconazole exposure and antifungal
resistance rates against fluconazole (p Z 0.023) and keto-
conazole (p Z 0.021), and there was a borderline associa-
tion between fluconazole exposure and voriconazole
resistance [p Z 0.054 (Table 3)]. No association was
observed between fluconazole resistance and the use of
nontriazole antifungal agents, such as amphotericin B or
nystatin, and the duration of fluconazole exposure. Other
factors including demographics, underlying diseases, and
invasive procedures that were related to resistance toward
antifungal agents, including triazoles, amphotericin B, and
caspofungin, were not identified.Discussion
The current study revealed that most Candida isolates
(71.7%) were still susceptible to fluconazole, except for
C. glabrata isolated from urine and other nonblood speci-
mens (100% were nonsusceptible). All Candida isolates
demonstrated 100% susceptibility to amphotericin B and
caspofungin, except 40.7% of the 27 C. glabrata, which
showed intermediate resistance to caspofungin. Vor-
iconazole, a new triazole, also had better activity against
all Candida isolates relative to fluconazole, except for
seven urine isolates that were resistant to voriconazole. A
review of invasive candidiasis in Taiwan [2] and a recent
nationwide survey [4] also revealed little variation in the
species distribution of clinical Candida isolates based on
geographic and secular differences, and around one-half of
the Candida isolates were C. albicans, which was similar to
the results of this study. These results differ from those of
studies in North America [18] and Ireland [19], in which the
prevalence of nonalbicans Candida was higher, especially in
patients who had cancer and among those who were criti-
cally ill. This was probably related to the common appli-
cation of fluconazole prophylaxis. A major secular change
in fluconazole susceptibility was noted as a shift from
susceptible to susceptible-dose dependent for C. glabrata
isolates despite the stable fluconazole resistant rates
demonstrated in several studies [2,4,6]. A previous survey
reported that Candida isolates in southern Taiwan had
a higher fluconazole resistance rate (11.8%) compared with
those in northern and central Taiwan (2.5% and 6.5%) [20].
Table 3 The relationship of fluconazole exposure and geome
Candida species.
Geometric means of
MIC
Fluconazole exposure Yes No
C. albicans
Numbers: (86) (47) (39)
Fluconazolea 0.791 0.635
Itraconazole 0.055 0.055
Ketoconazole 0.018 0.012
Voriconazole 0.017 0.016
C. tropicalis
Numbers: (41) (27) (14)
Fluconazolea 1.526 1.465
Itraconazole 0.180 0.160
Ketoconazole 0.039 0.028
Voriconazole 0.075 0.081
C. glabrata
Numbers: (26) (11) (15)
Fluconazolea 48.457 7.326
Itraconazole 6.122 0.756
Ketoconazole 0.692 0.168
Voriconazole 0.838 0.193
CLSI Z Clinical and Laboratory Standards Institute; MIC Z minimum
a Antifungal susceptibility test interpretive category by updated CL
Figure 3. Dendrogram of pulsed field gel electrophoresis
results for 27 C. glabrata isolates.
312 T.-C. Chen et al.However, the method used to collect isolates in that study
(10 C. albicans and 40 non-albicans from each hospital) did
not reflect the species distribution; therefore, this might
have influenced the drug resistance rate because different
species of Candida have different resistance tendencies to
various drugs. Each hospital in Taiwan had a different
resistance rates to fluconazole, which ranged from 0% to
24% [21]. C. glabrata isolates in southern Taiwan were
found to have a higher fluconazole nonsusceptible rate
(40%) than isolates in northern (29%) and central (14%)
regions [5]. Our study, conducted in a hospital in southern
Taiwan, showed a serious threat of triazole resistance for
C. glabrata. Clinicians should there be alert to the link
between triazole resistance and this species of Candida
when prescribing antifungal agents. Since routine anti-
fungal susceptibility testing is not recommended [22],
survey data of resistance rates for each species are
necessary to assist the clinician in choosing antifungal
agents.
We compared the susceptibility pattern reported in 1997
[7] in our hospital to the data in this current study
(Table 4). A lower susceptibility rate (64.7%) of C. tropicalis
blood isolates for amphotericin B was found in 1997
compared with the 100% susceptible rate observed in this
study. A low susceptibility rate (48.1%) of C. glabrata
isolates to fluconazole was a significant finding when
compared with the 1997 data. The observations that 35% of
C. glabrata isolates from urine specimens were resistant to
voriconazole and the cross-resistance phenomenon among
triazoles make amphotericin B and caspofungin choices
when triazole treatment fails when fluconazole was sug-
gested by guideline as the first-line treatment for candi-
duria [23]. Although echinocandins were proven useful fortric means of MICs and resistance percentages in different
p value Resistance (%) p value
Yes No
0.216 2.12% 0% 1.000
0.976 2.12% 0% 1.000
0.084 2.12% 0% 1.000
0.429 2.12% 0% d
0.904 12.50% 14.29% 1.000
0.811 21.43% 11.11% 0.328
0.263 0% 0% d
0.770 0% 0% d
0.012 54.55% 7.14% 0.023
0.006 81.82% 46.67% 0.109
0.028 54.55% 6.67% 0.021
0.051 45.45% 6.67% 0.054
inhibitory concentration.
SI criteria (2011).
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Fluconazole use and triazole cross-resistance 313treating triazole cross-resistant C. glabrata infections [24],
echinocandins have low urine concentrations and are not
recommended for treating urinary tract infections. As such,
nephrotoxic agents, such as amphotericin and flucytosine,
should be used for fluconazole-resistant candiduria. The
possible role of drug efflux pumps, including CgCDR1/2 and
MDR1, induced by triazole administration has been
demonstrated in clinical cases [25e27] and in vitro studies
[28e30]. The high diversity of pulsotypes and lack of clonal
spreading of triazole-resistant C. glabrata in the hospital
indicated that the high resistant rates to triazoles among
the C. glabrata isolates was not due to an occult outbreak
within the hospital. C. glabrata was found to be related
with previous antifungal use in epidemiological analysis and
a higher resistance rate to triazoles indicated the existence
of multiple triazole-resistant clones within the hospital
setting. Three studies also supported the observation that
previous fluconazole exposure is associated with the
development of fluconazole-resistant C. glabrata fungemia
[31e33]. Our results are different from three previous local
studies that have reported specific clones with fluconazole
resistance were circulating in hospitals in Taiwan [34e36].
Similar to the previously reported strong positive corre-
lation of fluconazole and voriconazole MICs [37], here we
report that the MICs of the four triazole drugs were highly
correlated. With regard to the four triazole drugs, the
lowest rate of susceptibility was to itraconazole (63.9%),
with susceptible rates of 87.3% to ketoconazole, 88% to
fluconazole, and 95.8% to voriconazole. It is noteworthy
that these isolates were collected before the introduction
of voriconazole use in the hospital, so there was no selec-
tion pressure for resistance to voriconazole. The presence
of voriconazole resistance, though at a low rate, may have
originated from the cross-resistance towards other triazoles
used. Fluconazole has been reported to be a surrogate
marker for susceptibility to ravuconazole [38], voriconazole
[39], and posaconazole [40]. We compared these three
older triazoles, and all demonstrated good correlation of
their MICs to voriconazole. However, only the CLSI break-
points of fluconazole susceptibility had a significant corre-
lation to the susceptibility to voriconazole. Therefore,
susceptibility and resistance to fluconazole can be a potent
predictor for susceptibility to voriconazole. No amphoter-
icin B resistant or caspofungin resistant isolate was found in
this hospital survey, indicating the effectiveness of the two
drugs; however, there is an alert for amphotericin B and
fluconazole resistant isolates in Taiwan [20].
There were some limitations in the current study. First,
the Candida isolates we analyzed were collected between
2003 and 2004. The Candida species distribution and anti-
fungal susceptibility may have changed since then.
However, we used the isolates from 2003 to 2004 because
we wanted to analyze the antifungal susceptibility and
epidemiology before introducing voriconazole in Taiwan to
exclude the impact of voriconazole itself. Second, the MIC
values in the current study were determined by E-test
method instead of the standard broth dilution method in
the CLSI guideline. Nevertheless, the results by E-test
showed good correlation with those by broth dilution test
[8e10].
In conclusion, C. albicans was the most common species,
and most Candida isolates in the current study were
314 T.-C. Chen et al.susceptible to fluconazole, except for the emergence of
triazole cross-resistant C. glabrata from urine specimens.
The cross-resistant C. glabrata were associated with
previous fluconazole exposure as opposed to clonal
spreading. Fluconazole was a good predictor for suscepti-
bility to voriconazole, and indeed better than itraconazole
or ketoconazole. Amphotericin B and caspofungin retained
excellent activity toward all Candida species, even toward
triazole-resistant C. glabrata. Clinicians should be cautious
of triazole cross-resistance, especially for patients with
prior fluconazole prophylaxis or treatment and for patients
with a risk for C. glabrata infections. According to the new
clinical practice guidelines for the management of candi-
diasis by the Infectious Diseases Society of America [23],
echinocandins or lipid-formulation amphotericin B should
be considered in these cases.
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